To the Brink and Back: How Caregiving Strengthened Our Relationship

Increasing the levels of a membrane-repair protein called tripartite motif containing 72 (TRIM72) protected against lung cell injury and lessened lung fibrosis in a mouse model of idiopathic pulmonary fibrosis (IPF). These data suggest that targeting TRIM72 or other membrane-repair molecules could be a treatment approach for IPF. The study,…

Many Pulmonary Fibrosis News readers know that during the last few months, I have had several acute illnesses. As a patient living with idiopathic pulmonary fibrosis (IPF), a life-threatening lung disease, I ended up quite sick as a result. Since mid-November, I have been recovering from pneumonia, influenza A, strep…

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease that few people — sometimes even physicians — have heard of is challenging on its own merit.

People who have a history of a cough, accompanied by worsening shortness of breath and weight loss, should be assessed for idiopathic pulmonary fibrosis (IPF), a recent study suggests. This conclusion was based on an analysis of past patient records in the U.K., which sought to understand the pattern…

A drop in air pollution due to COVID-19 restrictions has eased overall symptoms for about one in every six people diagnosed with respiratory disorders, a British Lung Foundation (BLF) survey of more than 14,000 people in the U.K. revealed. These findings prompted the Taskforce for Lung Health — a coalition…

Last week I wrote a column about energy expenditures and how I choose where to invest my energy in the multiple tasks vying for my attention. Unfortunately, since being diagnosed with idiopathic pulmonary fibrosis (IPF) four years ago, I just can’t give everything the energy I’d like. As a…

Idiopathic pulmonary fibrosis (IPF) patients taking antifibrotic therapies Ofev (nintedanib) or Esbriet (pirfenidone) had a mortality risk that was 37% lower than patients not treated with such therapies, a large registry-based study reports. The study, “Survival and Course of Lung Function in the Presence or Absence of Antifibrotic Treatment…